Pahl Pharmaceutical Professionals LLC — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$602,685	55
2024	Research	$955,000	104
2023	Research	$632,297	45
2022	Research	$216,083	30
2021	Research	$191,231	12
2020	Research	$441,913	14
2019	Research	$8,268	12

Breakdown

Who paid Research payments · program years 2019–2025

Indivior Inc. $1,920,128 221 payments
Sage Therapeutics, Inc. $1,087,010 48 payments
Otsuka Pharmaceutical Development & Commercialization, Inc. $40,338 3 payments

Studies the money was for Research payments · program years 2019–2025

A Phase II Double Blind, Placebo Controlled, Randomised, Dose-Ranging Study to Assess the Safety and Efficacy of Indv-2000 Over 3 Months in Treatment Seeking Individuals With Opioid Use Disorder $919,788 18 payments
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (Rbp-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-Risk Opioid Use $853,390 83 payments
A Phase 3, Open-Label, 1-Year Study of the Safety, Tolerability, and Need for Re-Treatment With Sage-217 in Adult Subjects With Major Depressive Disorder $339,295 28 payments
A Phase 3, Open-Label, 1-Year Study of the Safety, Tolerability, and Need for Re-Treatment with SAGE-217 in Adult Subjects with Major Depressive Disorder $296,579 2 payments
217-Mdd-303 $223,282 4 payments
A Comparative Study of Sage-217 Plus Sertraline Versus Placebo Plus Sertraline in Adults With Major Depressive Disorder $218,354 13 payments
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use $93,586 8 payments
A Phase IV Longitudinal Study of SUBLOCADE (SUBUTEX Prolonged Release) Clinical Outcomes in Adults With Opioid Use Disorder (Opioid Dependence) $36,797 97 payments
Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD $23,508 1 payment
A Phase 3, Multicenter, Randomized, Double-Blind Trial of Fixed-Dose Brexpiprazole As Combination Therapy With Sertraline in the Treatment of Adults With Post?Traumatic Stress Disorder $14,530 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.